• Company
• Will the ATTR-CM drug 'Vyndamax' receive reimb approval?
• by Eo, Yun-Ho Oct 25, 2024 05:49am

• Product
• AZ seeks to reaffirm Tagrisso’s position in NSCLC
• by Moon, sung-ho Oct 25, 2024 05:49am

• Company
• K-new drugs Rosuzet·K-CAB dominate the prescription market
• by Chon, Seung-Hyun Oct 25, 2024 05:48am

• Policy
• Reimb discussions restart for BMS’s Camzyos in KOR
• by Lee, Tak-Sun Oct 25, 2024 05:48am

• Policy
• MFDS says 'no procedural issues' regarding 'Leqembi'
• by Lee, Hye-Kyung Oct 24, 2024 05:52am

• Company
• Biktarvy’s indication expanded to patients 6yrs and older
• by Whang, byung-woo Oct 24, 2024 05:52am

• Company
• Reimb of the dyslipidemia drug Leqvio at a halt?
• by Eo, Yun-Ho Oct 24, 2024 05:52am

• Policy
• 'Preferential drug pricing for K-made new drugs' revision
• by Lee, Jeong-Hwan Oct 24, 2024 05:52am

• Policy
• Will non-face-to-face prescriptions of Wegovy be banned?
• by Lee, Jeong-Hwan Oct 24, 2024 05:51am

• Policy
• Overseas direct purchases of GLP-1 obesity drugs banned
• by Lee, Hye-Kyung Oct 23, 2024 05:50am